Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors
- Conditions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00436761
- Locations
- 🇺🇸
Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT00427765
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Donor Stem Cell Transplantation for Congenital Immunodeficiencies
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2021-05-11
- Target Recruit Count
- 48
- Registration Number
- NCT00426517
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00423826
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant
- Conditions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Registration Number
- NCT00417053
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Myelodysplasia-Related ChangesAdult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 546
- Registration Number
- NCT00416598
- Locations
- 🇺🇸
Northwell Health NCORP, Lake Success, New York, United States
🇺🇸Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 145
- Registration Number
- NCT00410982
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
- Conditions
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 53
- Registration Number
- NCT00408447
- Locations
- 🇺🇸
Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University, New York, New York, United States
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00402558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 3
- Registration Number
- NCT00363467
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.